Bay City Capital
Venture capitalSan Rafael · Seed–Late Stage · 8 people tracked
Also known as BAY CITY CAPITAL LLC
Investment thesis
Bay City Capital is a life sciences investment firm that invests across a diversified strategy from seed stage to public companies, concentrating largely on the development of breakthrough therapeutics. In this initiative it partnered with Takeda, Deerfield Management, and three leading New York research institutions (Memorial Sloan Kettering, The Rockefeller University, and Weill Cornell Medicine) to launch Bridge Medicines, a drug discovery company that funds and professionally manages early-stage academic projects from proof-of-concept through IND filing and clinical development.
Source: firm website, verified Aug 25, 2026.
Team · 8 people
from the firm's website & public directories
What they invest in
from 30 of 83 portfolio companiesBiotech ×23Healthtech ×13Medical Devices ×8Digital Health ×3Consumer ×2Deep Tech ×2AI & Machine Learning ×1Direct to Consumer ×1
HQs:United States×27Switzerland×2
Who they back
founder profiles across 14 portfolio companiesFounding team size:solo founder×52 founders×43 founders×34+ founders×2
Investments · 83 tracked
founders shown can be your intro pathBy year:2025 · 12019 · 12017 · 22016 · 22015 · 22014 · 210 dated
Advancing potentially best-in-class therapeutics for myeloproliferative neoplasms.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)Lori Firmani(Executive Officer)Hans T. Schambye(Executive Officer, Director)
BoardChristopher Cain(Director)Peter Harwin(Director)
Board seatCarl Goldfischer· per SEC Form D · $285M raise · filed Nov 2025
Co-investorsAccess BiotechnologyEIR Ventures
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)Robert Hopfner(Director)
Board seatCarl Goldfischer· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)RA CapitalArix BioscienceOrbiMed
BiotechLouisville, US
Nevan Elam(Executive Officer, Director)Sankaram Mantripragada(Executive Officer)Nevan Charles Elam(Executive Officer, Director)Morgan Lynn Fields(Executive Officer)
BoardHoyoung Huh(Director, Executive Officer)Barry Sherman(Director)
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Joshua Bilenker, M.D.(Director)
Co-investorsARCH Venture PartnersEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Samsara BioCapital
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)
Co-investorsCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan CapitalSofinnova Ventures+2 more
BiotechSouth Plainfield, US
Stuart W. Peltz(Executive Officer, Director)Allan S. Jacobson(Director)Mark E. Boulding(Executive Officer)Christine Utter(Executive Officer)Marcio Souza(Executive Officer)Neil Almstead(Executive Officer)
Co-investorsLongwood Fund
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
Emily Marine Leproust(Executive Officer, Director, Promoter)William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)in
BoardKeith Crandell(Director)Paul Conley(Director)in
Co-investors+ND Capital3E Bioventures CapitalARCH Venture PartnersAsset Management CompanyBlack Opal VenturesDentsu Ventures+7 more
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)
Co-investorsBain Capital Life SciencesF-Prime CapitalM VenturesMRL Ventures FundRA CapitalRiverVest Venture Partners+4 more
HealthtechSt Paul, US
Dan W Gladney(Executive Officer, Director)Scott P Youngstrom(Executive Officer)Rajesh Nihalani(Executive Officer)Peter M DeLange(Executive Officer)Paul F Hickey(Executive Officer)Naqeeb A Ansari(Executive Officer)
Board seatCarl Goldfischer· per SEC Form D
HealthtechSan Diego, US
John Hutchinson(Executive Officer)Vanessa Jacoby(Executive Officer)Robert Williamson(Executive Officer, Director, Promoter)
BoardRupert Vessey(Director)
Board seatCarl Goldfischer· per SEC Form D · $3M raise · filed Sep 2016
BiotechSacramento, US
George Barry(Co-Founder of Issuer)Philip H. Coelho(Chief Technology Officer and Co-Founder of Issuer)Chuck Novak(Vice President and Chief Financial Officer of the Issuer)William Gerber(Chief Executive Officer and President of Issuer)
BoardWoodrow A. Myers, Jr.(Director)
Board seatCarl Goldfischer· per SEC Form D
BiotechSouth San Francisco, US
Wendye Robbins(Executive Officer, Director)
BoardLuke Evnin(Director)inCameron Wheeler(Director)Peter van Vlasselaer(Director)Elaine Jones(Director)William Slattery(Director)
Co-investorsOUP (Osage University Partners)Pfizer Venture Investments+ND CapitalMPM BioImpact
Co-investorsNew Enterprise Associates (NEA)
BiotechChelsea, US
RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)MARK IWICKI(Executive Officer, Director)MARTIN FREED(Executive Officer)
BoardROB HOPFNER(Director)
Co-investorsCanaan PartnersSofinnova VenturesLongitude CapitalOrbiMedRA Capital
Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.
BiotechHealthtechMedical DevicesNewark, US
Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)
BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)
Co-investorsAvoro Capital AdvisorsForesite CapitalVantagePoint Capital Partners
HealthtechMenlo Park, US
THOMAS G. WIGGANS(Executive Officer, Director)EUGENE A. BAUER(Executive Officer, Director)Christopher M. Griffith(Executive Officer, Promoter)Luis C. Pena(Executive Officer, Promoter)Thomas G. Wiggans(Executive Officer, Director, Promoter)Eugene A. Bauer(Executive Officer, Director, Promoter)
Co-investorsAisling CapitalCanaan PartnersForesite CapitalNew Enterprise Associates (NEA)Fidelity InvestmentsQiming Healthcare+1 more
David Minkinin
Co-investorsMillennium Technology Value PartnersThreshold Ventures
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.
BiotechDeep TechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
Co-investorsGV (Google Ventures)LAVLilly Asia Ventures
Addressing unmet needs in gastroenterology and hepatology.
BiotechBrisbane, US
Christine Nash(Executive Officer)Natalie Holles(Executive Officer)Ashley Gould(Executive Officer)Donald J. Santel(Executive Officer)Klara A. Dickinson(Executive Officer)Bruce F. Scharschmidt(Executive Officer)
Co-investorsSofinnova Ventures
Biopharmaceutical company developing innovative therapies for chronic diseases using proprietary drug delivery systems.
BiotechBoston, US
James Ahlers(Executive Officer)John Yee(Executive Officer)Sunita Zalani(Executive Officer)Raymond T. Keane(Executive Officer)Thomas Alessi(Executive Officer)Owen Hughes, Jr.(Executive Officer)
Co-investorsCycad Group LLCForesite CapitalNXT Ventures
BiotechWatham, US
Kenneth Kornman(Executive Officer, Director)inStephen DiPalma(Executive Officer)
BoardJoseph Landstra(Director)Lionel Carnot(Director)Dayton Misfeldt(Director)James Weaver(Director)
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Michael W. Dunne(Executive Officer, Promoter)Corey N. Fishman(Executive Officer, Director, Promoter)Judith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)
BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)
Co-investorsCanaan PartnersSofinnova VenturesFrazier Life SciencesSofinnova Venture Partners
KBP is a biotechnology research and development organization that discovers and develops new therapies for unmet medical needs.
Biotech
Co-investorsHM Venture Partners
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)Christopher J. Kirk(Executive Officer, Director)
BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)
Co-investorsChiesi VenturesPappas CapitalSolasta Ventures
Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH).
BiotechHealthtechMedical DevicesConshohocken, US
Rebecca Taub(Founder and Director)
Co-investorsAvoro Capital Advisors
Nevro develops spinal cord stimulation systems for pain management, offering the Senza Trial Stimulator with high-frequency therapy options and wireless capability for patient trials and treatment.
AI & Machine LearningDigital HealthHealthtechMedical DevicesRedwood City, US
Co-investorsNew Enterprise Associates (NEA)
Medical DevicesNew Jersey, US
Co-investorsF-Prime CapitalSofinnova Ventures
Oculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments.
BiotechHealthtechMedical DevicesBoston, CH
Riad Sherif(Chief Executive Officer)
Co-investorsBrunnur Ventures GPVI Partners
Co-investorsNew Enterprise Associates (NEA)
Firmenich is a co-creation and innovation partner specializing in nutrition, health, and beauty ingredients and solutions.
ConsumerHealthtechNew MaterialsGeneva, CH
Gilbert Ghostinein
Co-investorsProspect Venture PartnersRho Ventures
Co-investorsVenrock
Co-investorsF-Prime Capital
Tria manufactures FDA-cleared at-home laser hair removal devices that use diode laser technology for permanent hair reduction.
ConsumerDirect to ConsumerHardwareHealthtechWellness & FitnessDublin, US
TOBIN C. ISLAND(Executive Officer)KEVIN J. APPELBAUM(Executive Officer, Director)DEREK YUNG(Executive Officer)DANIKA HARRISON(Executive Officer)JIYOUNG CHOI(Executive Officer)CHARLES BRACHER(Director)
Co-investorsAisling CapitalIncubic Management LLC
Developing oncology therapeutics for viral-induced tumors; went public February 2021 (VIRX).
Co-investorsaMoonLatterell Venture Partners
Vivaldi Biosciences develops Delta NS1 vaccines designed to protect against epidemic and pandemic viral respiratory diseases.
BiotechHealthtechMedical DevicesFort Collins, US
Peter Palese(Founder & Scientific Advisor)Adolfo García-Sastre(Founder & Scientific Advisor)Elliott Kieff(Founder & Scientific Advisor)William Wick(CEO, Board Member and Managing Director)
Co-investorsNGN Capital
BiotechAustin, US
Steven Prestrelski(Executive Officer)Douglas Baum(Executive Officer, Director)John Kinzell(Executive Officer, Director)Poul Strange(Executive Officer)Yash Sabharwal(Executive Officer)
BoardRobert Faulker(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 9
IPOs and acquisitions across the tracked portfolioDamora TherapeuticsNASDAQ: DMRAImaraNASDAQ: ELVNAntriaBioNASDAQ: RZLTGossamer BioNASDAQ: GOSSNextCureNASDAQ: NXTCPtc TherapeuticsNASDAQ: PTCTTwist BioscienceNASDAQ: TWSTXilio TherapeuticsNASDAQ: XLONextwavepharmaacq. by Tris Pharma
Portfolio news
latest coverage across their companiesXilio Therapeutics · tickerreport.com · Aug 15, 2026
Imara · trysignalbase.com · Jul 24, 2026
NextCure · investing.com · Jul 15, 2026
Frequently asked questions
- How many investments has Bay City Capital made?
- Bay City Capital has 80 tracked investments, 3 of which have exited via acquisition or IPO.
- What stage does Bay City Capital invest at?
- Bay City Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Bay City Capital's typical check size?
- Bay City Capital typically writes checks of $5M – $10M.
- What sectors does Bay City Capital focus on?
- Bay City Capital focuses on Biotech, Digital Health, Enterprise Software, Healthtech, Medical Devices.
- Where is Bay City Capital located?
- Bay City Capital is headquartered in San Rafael, US.
- Who does Bay City Capital co-invest with?
- Bay City Capital most often shares deals with New Enterprise Associates (NEA), Canaan Partners, F-Prime Capital, among 52 tracked co-investors.
Media · Podcasts & interviews
featuring the teamSimilar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Norwest Venture Partners is an investment firm whose growth equity team backs private, profitable, fast-growing companies, providing capital and hands-on support through its 'invited guest' approach.
OneVentures is a later-stage venture capital firm that backs technology and healthcare companies, providing growth equity and credit alongside strategic and operational support.